Anuh Pharma Ltd
₹ 76.9
1.00%
01 Jun
- close price
About
Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals[1]
Key Points
- Market Cap ₹ 770 Cr.
- Current Price ₹ 76.9
- High / Low ₹ 115 / 66.7
- Stock P/E 18.8
- Book Value ₹ 35.1
- Dividend Yield 1.95 %
- ROCE 15.9 %
- ROE 12.1 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 24.4%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 772 | |
| 253 | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 710 | |
| Operating Profit | 31 | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 62 |
| OPM % | 11% | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% | 9% | 8% |
| 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 4 | |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 0 |
| Depreciation | 3 | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 11 |
| Profit before tax | 32 | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 54 |
| Tax % | 31% | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | 23% | 22% | 24% |
| 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 41 | |
| EPS in Rs | 2.19 | 2.57 | 2.00 | 1.65 | 2.33 | 1.43 | 2.84 | 3.05 | 3.61 | 5.99 | 4.73 | 4.10 |
| Dividend Payout % | 27% | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% | 21% | 16% | 37% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 12% |
| 3 Years: | 14% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 13% |
| 3 Years: | 8% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 3% |
| 3 Years: | 20% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 15% |
| 3 Years: | 15% |
| Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 13 | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 | 25 | 50 |
| Reserves | 97 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 | 302 |
| 0 | 2 | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 3 | 11 | 0 | |
| 67 | 71 | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 152 | 170 | 205 | |
| Total Liabilities | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 |
| 9 | 18 | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | 57 | |
| CWIP | 0 | 0 | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 43 | 43 | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 | 84 |
| 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | 342 | 416 | |
| Total Assets | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | 16 | 26 | 2 | 7 | 49 | -19 | 29 | 54 | 13 | 37 | -3 | |
| -12 | -5 | -20 | 2 | 3 | -77 | 52 | -8 | -43 | 1 | -20 | 18 | |
| -8 | -9 | -4 | -5 | -7 | 22 | -33 | -19 | -12 | -9 | -5 | -26 | |
| Net Cash Flow | -1 | 2 | 2 | -1 | 3 | -5 | 0 | 2 | -2 | 5 | 12 | -12 |
| Free Cash Flow | 18 | 6 | 25 | -5 | -22 | 13 | -25 | 27 | 52 | 8 | 17 | -11 |
| CFO/OP | 96% | 78% | 149% | 49% | 56% | 232% | -20% | 80% | 130% | 42% | 78% | 17% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 | 119 | 113 |
| Inventory Days | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 | 90 |
| Days Payable | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 | 114 |
| Cash Conversion Cycle | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 | 59 | 89 |
| Working Capital Days | 43 | 48 | 79 | 80 | 65 | -10 | 57 | 68 | 61 | 69 | 68 | 114 |
| ROCE % | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% | 26% | 17% | 16% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Installed Capacity MTPA |
|
|||||||||||
| Production/Sales Volume MT |
||||||||||||
| Net Working Capital Days Days |
||||||||||||
| Capacity Utilization % |
||||||||||||
| Effluent Treatment Capacity KL/day |
||||||||||||
| Global Presence (Countries) Number |
||||||||||||
| Number of Active Customers Number |
||||||||||||
| Number of API Blocks Number |
||||||||||||
| Number of Intermediate Blocks Number |
||||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - FY2026 secretarial compliance report filed; past INR 2,14,760 BSE fine waiver pending.
- Announcement under Regulation 30 (LODR)-Investor Presentation 28 May
-
Intimation Pursuant To Regulation 31A Of SEBI (LODR) Regulations, 2015
25 May - Applied on 25 May 2026 to reclassify nine promoter-group holders to public, totaling 9,49,988 shares.
-
Intimation Pursuant To Regulation 31A Of SEBI (LODR) Regulations, 2015
22 May - Board approved reclassification of nine promoter group shareholders to public category under Regulation 31A, subject to approvals.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
22 May - Newspaper Publication of the Audited financial results for the Quarter and Year ended 31st March, 2026, published in the Financial Express in English Language and …
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptAI SummaryPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Aug 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Aug 2019TranscriptAI SummaryPPT
-
Dec 2017TranscriptAI SummaryPPT
-
Feb 2016TranscriptAI SummaryPPT
-
Dec 2015TranscriptAI SummaryPPT
-
Sep 2015TranscriptAI SummaryPPT
-
Aug 2015TranscriptAI SummaryPPT
Business Overview:[1][2]
a) APL is a part of the SK Group and is a leading manufacturer of Macrolides and Anti-TB products in India, besides being a major player in Anti-bacterials, Anti-malarial, Anti-hypertension, and Corticosteroids.
b) It is a medium-sized player in the API/bulk drugs industry, manufacturing products such as erythromycin and its salts, and higher macrolides like azithromycin, roxithromycin, pyrazinamide, and chloramphenicol.
c) The company claims to be the largest producer of erythromycin salts in India and among the top five globally. It is also the largest producer of pyrazinamide in the world.
d) APL has marketing partnerships with 350 customers in over 57 countries, including Europe, Mexico, and South Africa.